ACE-031vsTesamorelin

ACE-031 is a recombinant fusion protein consisting of the extracellular domain of the activin type IIB receptor (ActRIIB) linked to the Fc portion of human IgG1 antibody. This design creates a soluble 'decoy receptor' that circulates in the bloodstream and intercepts TGF-beta superfamily ligands before they can bind to membrane-bound ActRIIB receptors on target tissues.

The therapeutic power — and the safety challenge — of ACE-031 lies in its broad ligand-binding profile. While follistatin primarily targets myostatin and activin, ActRIIB is the shared receptor for multiple TGF-beta family members including myostatin (GDF-8), activin A, activin B, GDF-11, and BMP-9/BMP-10. By trapping all of these simultaneously, ACE-031 produces rapid and dramatic increases in lean muscle mass — in clinical trials, subjects gained measurable lean mass within 2-4 weeks without exercise. The removal of myostatin allows unrestricted myogenic differentiation and protein synthesis, while blocking activin further enhances this effect.

However, the broad ligand trap mechanism also blocks BMP-9 and BMP-10, which are critical regulators of vascular endothelial homeostasis and angiogenesis. BMP-9 signaling through ALK1 (activin receptor-like kinase 1) on endothelial cells maintains vascular integrity and prevents the formation of aberrant blood vessel structures. Blocking this pathway produces the same vascular defects seen in hereditary hemorrhagic telangiectasia (HHT), a genetic condition caused by mutations in the ALK1/endoglin/BMP-9 pathway — specifically, nosebleeds, gum bleeding, and telangiectasias (dilated superficial blood vessels). It was these vascular side effects that forced Acceleron Pharma to halt the Duchenne muscular dystrophy clinical trial, demonstrating the difficulty of using broad-spectrum ligand traps without off-target effects.

Tesamorelin is a synthetic GHRH analogue consisting of all 44 amino acids of human GHRH with a trans-3-hexenoic acid group attached to the tyrosine at position 1. This lipophilic modification enhances receptor binding affinity and provides modest resistance to dipeptidyl peptidase-IV (DPP-IV) cleavage, improving its pharmacokinetic profile compared to native GHRH.

Like other GHRH analogues, tesamorelin activates the GHRH receptor on pituitary somatotrophs via the Gs/cAMP/PKA pathway, stimulating endogenous GH synthesis and pulsatile secretion. The resulting increase in circulating GH and IGF-1 produces its primary therapeutic effect: targeted reduction of visceral adipose tissue (VAT). GH-mediated lipolysis is particularly active in visceral fat depots because these adipocytes have the highest density of GH receptors and are most responsive to GH-stimulated hormone-sensitive lipase activation.

The specificity of tesamorelin's effect on visceral rather than subcutaneous fat has been well-documented in clinical trials. Visceral adipose tissue is metabolically distinct — it drains directly into the portal circulation and contributes disproportionately to hepatic insulin resistance, inflammatory cytokine production, and cardiovascular risk. By selectively reducing this depot, tesamorelin improves the cardiometabolic profile beyond what would be expected from total fat loss alone. Clinical trials also showed improvements in hepatic steatosis (fatty liver) markers, triglyceride levels, and trunk fat distribution. It remains the only GHRH analogue with active FDA approval, specifically for HIV-associated lipodystrophy, where visceral fat accumulation is a common and distressing side effect of antiretroviral therapy.